Past Tuesday Talks — A Deep Dive Into Gene Therapies of the Future
Tuesday, July 18, 2023
Presented by Seema Kumar, CEO, Cure
On Tuesday, July 18th, Nolan Townsend, CEO of LEXEO Therapeutics. Nolan took us through a thoughtful perspective about the power of gene therapy and how LEXEO is utilizing therapies to solve some of the world’s most devastating diseases including Cardiovascular Disease and Alzheimer’s. Hosted by Seema Kumar, CEO of Cure.
Tuesday Talks: A Deep Dive Into Gene Therapies of the Future
Where: Virtual audience only on LinkedIn Live Topic: A fireside chat with R. Nolan Townsend CEO, LEXEO Therapeutics. In conversation with Seema Kumar, CEO, Cure.
About R. Nolan Townsend
R. Nolan Townsend has served as LEXEO Therapeutics Chief Executive Officer and member of the Board of Directors since January 2020. LEXEO Therapeutics is a New York City-based, clinical stage biotechnology company that aims to apply the transformational science of gene therapy to address some of the world’s most devastating genetic diseases. Prior to LEXEO, Mr. Townsend held roles as President, Pfizer Rare Disease for the North America region and President, Pfizer Rare Disease for the International markets; overseeing overall strategy, the cross functional organization and operating budget in those regions. Mr. Townsend has over a decade of experience with Pfizer first joining the company in Corporate Finance and subsequently in roles of increasing responsibility across Corporate Finance, Corporate Strategy, Operations, Marketing, General Management and Commercial leadership in Pfizer’s New York headquarters, Asia, Africa/Middle East and Europe. Prior to Pfizer, Mr. Townsend worked in the healthcare investment banking group at Lehman Brothers, advising healthcare companies on strategic financing transactions and mergers and acquisitions.
About Seema Kumar
Seema joined Cure Experience in 2022 as the Chief Executive Officer. Prior to Cure, Ms. Kumar spent nearly 20 years at Johnson & Johnson in senior leadership roles, including most recently as the Global Head, Office of Innovation, Global Health and Scientific Engagement, and served on J&J’s Innovation Strategy, Public health leadership and the COVID-19 vaccine steering committee, where she led the company’s external affairs efforts and public education program on COVID and vaccine literacy. Before her tenure at J&J, Ms. Kumar was the Chief of Staff to Dr. Eric Lander and the Chief Communications Officer at the Whitehead Institute/Massachusetts Institute of Technology Center for Genome Research where she played a leadership role in the Human Genome Project. She also has held leadership positions at the U.S. National Institutes of Allergy and Infectious Diseases (NIAID), the National Institutes of Health, and Johns Hopkins School of Medicine. Ms. Kumar holds an M.S. in Science Journalism and Communications from the University of Maryland.